The findings of a recent study may inform new approaches to treat Crohn’s disease by targeting disease-causing microbes in the gut.
The findings of a recent study suggest that mycobiota changes during a SARS-CoV-2 infection could contribute to inflammation associated with severe COVID.
The findings of a recent study indicate that effective treatments for recurrent UTIs may require the ability to penetrate human tissues.
Alessio Fasano gives an overview of the IHMC Congress to be held in Rome, 22-25 June.
Underpinning this partnership is a shared vision championed by both entities, emphasizing the interconnectedness of human, animal, and ecosystem health—a concept central to the 'One Health' approach.
Industry
Sponsored by
Join SynBalance, platinum sponsor at Probiota Global 2024 (7-9 February, Milan), and discover the newst scientific data on ProBeautyShield, the probiotic ingredient designed for skin health.
Focusing on restoring microbial cross-feeding interactions emerges as a promising mechanism-informed strategy to reconstruct a healthy gut ecosystem.
The findings of a recent study indicate that antibodies to gut microbes could help identify who may benefit from teplizumab.
Their work in engineering bacteriophages to target pathogenic bacteria represents a significant leap in treating bacterial and inflammatory diseases.
The partnership centers around the marketing of DUOSPORE®, a dietary supplement developed by My Health.
